Table 1.
Cross-reactive epitopes in the S2 of SARS-CoV-2 and other coronaviruses.
S2 amino acid residues1 | S2 region or domain2 | Virus strain | Mode of induction | Study |
---|---|---|---|---|
S785−840 | FP | SARS-CoV-2 | Natural infection | [46] |
S809−826 | FP | SARS-CoV-2 | Natural infection | [80] |
S809−834 | FP | SARS-CoV-2 | Natural infection | [81] |
S810−816 | FP | SARS-CoV-2 | Natural infection | [32] |
S811−830 | FP | SARS-CoV-2 | Natural infection | [31] |
S813−868 | FP | SARS-CoV-2 | Natural infection | [46] |
S817−824 | FP | SARS-CoV-2 | Natural infection | [32] |
S819−824 | FP | SARS-CoV-2 | Natural infection | [47] |
S851−856 | FP | SARS-CoV-2 | Natural infection | [32] |
S910−1213 | HR1 to HR2 | SARS-CoV-2 | Immunisation | [82] |
S980−1006 | HR1 to CH | MERS-CoV | Immunisation | [90] |
S997−1002 | CH | SARS-CoV-2 | Natural infection | [32] |
S1040−1044 | CH | SARS-CoV-2 | Natural infection | [32] |
S1041−1207 | CD-SH-HR2 | SARS-CoV | Natural infection | [86] |
S1073−1210 | CD-SH-HR2 | SARS-CoV | Immunisation | [83] |
S1109−1148 | CD-SH | SARS-CoV | Immunisation | [84] |
S1121−1176 | CD-SH-HR2 | SARS-CoV-2 | Natural infection | [46] |
S1140−1168 | SH-HR2 | SARS-CoV-2 | Natural infection | [81] |
S1144−1163 | SH | SARS-CoV-2 | Natural infection | [31] |
S1147−1161 | SH | SARS-CoV-2 | Immunisation | [89] |
S1148−1156 | SH | SARS-CoV-2 | Natural infection | [74] |
S1149−1204 | SH-HR2 | SARS-CoV-2 | Natural infection | [46] |
S1150−1157 | SH | MERS-CoV | Immunisation | [87] |
S1150−1156 | SH-HR2 | SARS-CoV-2 | Natural infection | [47] |
S1169−1188 | HR2 | SARS-CoV | Immunisation | [84] |
S1169−1210 | HR2-MP | SARS-CoV | Immunisation | [84] |
S1205−1212 | MP | SARS-CoV-2 | Natural infection | [32] |
Amino acid numbering refer to SARS-CoV-2 S.
FP: fusion peptide; HR1, heptad repeat 1; CH, central helix; CD, connecting domain; SH, stem helix; HR2, heptad repeat 2; MP, membrane proximal.